4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume – Time to Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares saw strong trading volume on Friday . 2,782,783 shares changed hands during mid-day trading, an increase of 269% from the previous session’s volume of 753,612 shares.The stock last traded at $9.7830 and had previously closed at $8.97.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Royal Bank Of Canada lifted their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.88.

4D Molecular Therapeutics Price Performance

The stock has a 50 day moving average price of $9.51 and a 200-day moving average price of $9.29. The stock has a market capitalization of $518.09 million, a price-to-earnings ratio of -3.86 and a beta of 2.77.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. As a group, research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.74 earnings per share for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics during the first quarter worth $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics during the third quarter worth $41,000. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics during the first quarter worth $46,000. Daiwa Securities Group Inc. boosted its stake in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new position in 4D Molecular Therapeutics during the second quarter worth $48,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.